Bio News
Qurient received approval from the Ministry of Food and Drug Safety for a combination trial of the CDK7 inhibitor mocaciclil and the ADC Trodelvy in patients with triple-negative breast cancer (TNBC). This is the first case in which a CDK7 inhibitor and an ADC with a TOP1 inhibitor payload will be administered together, using a mechanism that inhibits the DNA damage repair pathway. The company will evaluate whether the combination can enhance Trodelvy’s existing treatment effects and expand the range of eligible patients.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
